Application of cyclodextrin in preparation of medicine for treating and/or preventing polycystic kidney disease

A technology of polycystic kidney disease and cyclodextrin, which is applied in the direction of drug combination, pharmaceutical formula, urinary system diseases, etc., and can solve problems such as undiscovered cyclodextrin research

Inactive Publication Date: 2020-12-29
梅长林
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

There are currently no studies of cyclodext...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of cyclodextrin in preparation of medicine for treating and/or preventing polycystic kidney disease
  • Application of cyclodextrin in preparation of medicine for treating and/or preventing polycystic kidney disease
  • Application of cyclodextrin in preparation of medicine for treating and/or preventing polycystic kidney disease

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0047] Example 1 Effect of hydroxypropyl-β-cyclodextrin on polycystic kidney phenotype in knockout pkd1 mice

[0048] 1. Research on early induced mouse models

[0049] Fifteen newborn mice were randomly divided into three groups, 5 in each group, and divided into normal group, hydroxypropyl-β-cyclodextrin group and control group. The p-hydroxypropyl-β-cyclodextrin group and the control group were intraperitoneally injected with tamoxifen 10 mg / kg on the 10th day after birth to knock out pkd1, and the hydroxypropyl-β-cyclodextrin group was injected intraperitoneally every two days starting from the 13th day after birth -β-cyclodextrin solution (HP-beta-CD / HP-β-CD) (4mg / g), the control group was intraperitoneally injected with an equal dose of normal saline (Saline) at the same time, and the normal group was not subjected to pkd1 knockout. The mice were sacrificed on the 30th day after birth, and their blood was collected for HE staining of kidney tissue sections and renal fun...

Embodiment 2

[0058] Example 2 Study on the inhibitory effect of hydroxypropyl-β-cyclodextrin on CAV1 in polycystic kidney tissue

[0059] 1. Comparative study of CAV1 in human paracancerous kidney tissue and human polycystic kidney tissue

[0060] Human paracancerous kidney tissue and human polycystic kidney tissue were collected (sources were the renal tissue adjacent to renal cancer and the renal tissue of polycystic nephrectomy patients respectively, and the tissue acquisition was approved by the Ethics Committee of Changzheng Hospital, following the ethical norms ), the expression of CAV1 was analyzed by immunohistochemistry and Western blot, the results are shown in image 3 and Figure 4 .

[0061] The steps of the immunohistochemical experiment are as follows: human paracancerous kidney tissue and human polycystic kidney tissue were fixed with tissue fixative, embedded in paraffin, and then made into 2 μm sections. Bake the slices overnight at 55°C and dewax with xylene and ethan...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides an application of cyclodextrin in preparation of a medicine for treating and/or preventing polycystic kidney disease, and belongs to the technical field of biology. According tothe invention, an ADPKD model is applied to prove that after hydroxypropyl-beta-cyclodextrin removes a fossa structure on the surface of a polycystic kidney cyst tissue cell membrane, the expressionof caveolin-1 (CAV1) is reduced, so that the purpose of treating and/or preventing autosomal dominant polycystic kidney disease caused by gene mutation is achieved.

Description

technical field [0001] The invention belongs to the field of biotechnology, and in particular relates to the application of cyclodextrin in the preparation of medicines for treating and / or preventing polycystic kidney disease. Background technique [0002] The most common type of polycystic kidney disease is autosomal dominant polycystic kidney disease, and autosomal dominant polycystic kidney disease (ADPKD) is the most common monogenic hereditary kidney disease, mainly caused by pkd1 (about 78%) or pkd2 (about 15%) %) gene mutation, the global incidence is about 1 / 2500~1 / 1000. ADPKD is a systemic disease. The main clinical manifestation is the uncontrollable growth of renal cysts, which eventually leads to the loss of renal function and end-stage renal disease. At the same time, it also manifests as liver cysts, pancreatic cysts, hypertension and intracranial hemangioma outside the kidney. Wait. According to statistics, ADPKD ranks fourth among common kidney diseases tha...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/724A61P13/12
CPCA61K31/724A61P13/12
Inventor 梅长林陈思秀徐德超宋书伟付莉莉
Owner 梅长林
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap